Viral RNA-Based Sprays For Plants Have Unknown Consequences

This article was originally published by Rhoda Wilson at Natural News. 

Terrana Biosciences is on a mission to replace pesticides with its RNA-based sprays as “vaccines” for plants to protect crops from pests and diseases.  The RNA is taken from plant viruses. 

Terrana claims its sprays do not alter the plant genome and merely deliver RNA into plants to stimulate an immune response or produce protective proteins.  But in reality, they don’t know, as there have been no long-term safety studies.

The company describes its products as: “Terrana sources native RNAs from across the plant world and gives them new instructions to make any desired trait and solve for problems at any point in the plant’s lifecycle,” which indicates their true aim.

Michelle Perro explains why Terrana’s sprays are risky, very risky, for people and the environment. RNA sprays are more dangerous than GMO crops, she says.

Related: The architects of Moderna’s mRNA shots are plotting to spray RNA on your food, Natural News. 25 July 202

Terrana Biosciences was launched by the venture capital firm Flagship Pioneering on 1 July 2025.  At the end of July, reports were circulating that the company had received approval to spray synthetic RNA onto American food crops.  The reports (for example, see HERE and HERE) don’t provide their sources for the approval, so we haven’t been able to verify these claims.

However, in December 2023, the Environmental Protection Agency (“EPA”) approved ledprona, a sprayable double-stranded ribonucleic acid pesticide. Marketed as Calantha, which uses ledprona as its active ingredient, the RNA interference (“RNAi”) pesticide was developed by GreenLight Biosciences.

Perhaps the July reports are conflating the launch of Terrana Biosciences and the approval of GreenLight’s RNA products? Regardless, the whole agenda of replacing chemicals with RNA products is nefarious.

Table of Contents

GreenLight Biosciences, founded in 2008 and based in Massachusetts, is a biotechnology company that uses RNA technology to develop sustainable solutions for agriculture and human health.  “In Rochester, New York, we are operating the world’s largest RNA factory,” the company boasts.

It has received US regulatory approval to sell its RNAi pesticide for the Colorado potato beetle, Calantha, and is awaiting approval for Norroa, an RNAi product to “protect honeybees” from varroa mites.

In December 2024, GreenLight announced the establishment of GreenLight Biosciences México, S. de R.L. de C.V., expanding its operations to Brazil and Mexico.  “Among the innovative technologies to be introduced are a novel adjuvant that improves crop protection performance and Norroa,” the company said.

This year, GreenLight has received substantial funding.

In March 2025, the company announced a $25 million investment from Just Climate.  Just Climate was established in 2021 by Generation Investment Management as a “specialist investment business focused on scaling solutions for the highest-emitting, most off-track sectors of the economy.”

Generation Investment Management is an investment management firm founded in 2004 by former US Vice President Al Gore and former Goldman Sachs’ Asset Management head David Blood, along with five other partners. According to a report in 2017, the company had US$18 billion under management and was based in London with an office in San Francisco.  At the time, the company employed 100 people.  According to Wikipedia, it has partnerships with the following:

• Net Zero Asset Managers initiative
• The Climate Pledge
• Ceres
• The Alliance for Climate Protection (Repower America)
• World Resources Institute
• Natural Resources Defence Council
• The Climate Project

“[Just Climate’s] investment enables the company to continue its expansion across key international markets, including Brazil and other Latin American countries. Recent expansion efforts include the establishment of a state-of-the-art Agricultural Research Station in Seville, Spain, which now serves as the Company’s European hub for innovation and collaborative research in sustainable agriculture practices,” GreenLight Biosciences said.

In February 2025, the European Investment Bank (“EIB”) provided a €35 million loan to GreenLight Biosciences Spain to “support research and production of ribonucleic acid interference (RNAi)-based biocontrols.”  RNAi-based “biocontrols” (i.e. pesticides) “constitute a sustainable alternative to traditional chemical pesticides,” EIB said.

Adding, “The EIB loan will support GreenLight Bio’s RDI programmes associated with the research, registration, and production of a pipeline of ten products to be launched in the EU … The loan will also finance the research and innovation centre of Greenlight Biosciences in Seville, Spain.”

Now read the Globalist propaganda GreenLight uses to push its gene editing products.  Note the use of the phrase “nature-based pest control” and “environmentally friendly.”  It is an outright lie to claim that gene manipulation is “nature-based” or “environmentally friendly.”

“At GreenLight Biosciences, we believe that providing farmers with nature-based pest control solutions is key to building a more sustainable and resilient food supply chain. Our platform is not only environmentally friendly but also offers farmers an effective and safe alternative to traditional pesticides,” stated GreenLight Biosciences Chief Strategy Officer & co-founder Marta Ortega-Valle. “With the support of the European Investment Bank, we can expand our efforts to bring these innovative solutions to farmers across Europe.”

Spain: EIB finances GreenLight Biosciences with €35 million to invest in research and production of RNA-based biological pesticides, European Investment Bank, 3 February 2025

According to the company profile on Investing, GreenLight Biosciences is also involved in human health, with “a phase I/II preclinical stage vaccine for COVID-19 and candidate selection vaccines for shingles and oncology.”

We previously noted Flagship Pioneering in our article ‘UK’s plan to be a “science and technology superpower” progresses; dystopia looms’.  In this article, we quoted a Department for Science, Innovation & Technology policy paper which said:

US Venture Capital firm Flagship Pioneering announced its strategic commitment to the UK life sciences ecosystem in 2023 and established its first base outside of the US in London. This was marked by the signing of a Memorandum of Understanding (MoU) with the UK government … This commitment was combined with Flagship’s milestone launch of Quotient Therapeutics, the first Flagship-founded company co-anchored in the UK and US.

Innovation, investment and growth in life sciences – applying the Science and Technology Framework to one of the UK’s strongest sectors, The UK Science and Technology Framework: update on progress (9 February 2024), Department for Science, Innovation & Technology, 9 February 2024

In our 2021 article ‘Building an Empire – The United Nations Using the World Economic Forum to Roll Out Its Agenda’, we noted that “the top institutional shareholders of Moderna are Baillie Gifford & Company, and Flagship Pioneering Inc. (founded by Noubar Afeyan) followed by Vanguard, Blackrock and Morgan Stanley.”

In an article last year, ‘Moderna’s influence over the US and UK governments is more than most realise’, we noted: “Flagship Pioneering are a venture capital firm that financed and kickstarted Moderna. The CEO of Flagship Pioneering, Noubar Afeyan, also co-founded Moderna. So, they’re essentially one and the same.”

Wikispooks notes that “after Noubar Afeyan and Robert Langer, [Stéphane] Bancel is the largest individual shareholder in [Moderna].”

So, who is Flagship Pioneering?

Founded in 1999 by Noubar Afeyan and Ed Kania under the name NewcoGen, it was later renamed Flagship Ventures and then Flagship Pioneering in 2016. The company has originated and fostered more than 100 companies since its launch in 2000, resulting in over $60 billion in aggregate value. According to its LinkedIn profile, “The current Flagship ecosystem comprises over 40 companies.”  You can see a list of these companies HERE, one of which is Moderna.

In 2023, Flagship Pioneering established its first European base in London, marking a significant expansion into the UK life sciences sector. This move was followed by the launch of Quotient Therapeutics. At the beginning of this year, Flagship Pioneering partnered with Cambridge University Health Partners (“CUHP”) and the Milner Therapeutics Institute (MTI) to accelerate biotech research and innovation in the UK.  You can see a list of Flagship’s numerous partners HERE, including ThermoFisher, Novo Nordisk, Pfizer and GSK.  In 2025, Flagship unveiled Terrana Biosciences.

Forbes reported in 2021 that founder Noubar Afeyan owns at least 75% of Flagship Pioneering.

By Michelle Perro, MD, as published by GMO Science on 31 July 2025

Terrana Biosciences, launched by Flagship Pioneering, the creator of Moderna, received a $50 million initial investment and government approval for experimental-use authorisations, raising ethical and public health alarms.

The company pioneers RNA-based agricultural traits throughout a “proprietary technology platform.”  The company claims that their approach will empower farmers with “… precise, adaptive solutions to combat threats to crops in fields and orchards and enhance resiliency, sustainability, and productivity in the global food system.”

Is this an incredible breakthrough or more of the same rhetoric that we endured and heard spouted with genetically modified organisms (“GMOs”) that turned out to be an environmental and health disaster?

Instead of modifying DNA, Terrana’s spray-on RNA platform delivers engineered RNA molecules through tiny tears in plant leaves; these enter plant cells, replicate and can express proteins such as viral antigens, insecticidal Cry toxins, or climate‑resilience genes designed to act as programmable plant vaccines.

Thus, Terrana will use RNA from plant viruses as a chassis to carry pieces of “cargo RNA” into a plant to help it fight infections and insects, and deliver vaccines.

The CEO of Terrana (and a Flagship partner), Ryan Rapp, says we should think of this “… like software.  You can stick a floppy disk or USB drive into the computer and give it a set of instructions.  This is the first time we’ve had a platform where we can actually do this in plants”.

Terrana CEO Ryan Rapp: “We are giving humanity this other tool as we start to deal with climate change to help us deal with the effects on food supply and production.”

‘There are so many things we can do with this’… Terrana Biosciences to unleash RNA-based crop protection, Ag Tech Navigator, 3 July 2025

Kids aren’t software updates!  Keep synthetic RNA off their plates.

The approach by Terrana differs from those using RNA interference (“RNAi”) on crops.  The EPA gave the green light to farmers in 2024 to use an RNAi insecticide from GreenLight Biosciences. When consumed by beetles, the RNA silences their survival gene.

RNA sprays are deployed without long-term safety data on human exposure, children, or immune and reproductive effects. The technology remains unlabelled, and liability protections are in place under experimental regulatory frameworks.

Terrana’s products fall under experimental authorisation, meaning neither Terrana nor government agencies bear liability for adverse outcomes. There is no mandatory labelling, so consumers cannot give informed consent or opt out.

RNA molecules entering human food supplies may alter gut-associated lymphoid tissue (“GALT”), raising unknown immunological consequences in children.  Repeat exposure could disrupt hormonal signalling, endocrine pathways or even transgenerational development (affecting our offspring), given RNA’s potential systemic persistence.

Terrana claims some RNA constructs may be heritable across plant generations, raising an alarm about unintentional spread across species and ecosystems. This uncontrolled gene expression mirrors historically what we have witnessed with GMOs, only magnified by a sprayable, replicable system.

The fight against GMOs has been an uphill battle, with industry and regulatory agencies suppressing public awareness despite mounting and censored scientific evidence of harm.

This is the same pattern of secrecy and dismissal now repeating itself with the untested, unlabelled RNA spray technology being pushed onto our food and environment.

The EPA has already approved RNA-based applications such as GreenLight’s RNAi spray in 2024. Terrana’s RNA is more advanced: it enters the plant interior and replicates, rather than merely coating leaves like earlier RNA sprays.  Regulatory agencies have permitted early usage under experimental-use guidance, without labelling mandates and with pre-emption protections, shielding manufacturers from legal accountability.

What Could Go Wrong?

Terrana’s “software” approach to plants is far more dangerous than traditional GMOs because it bypasses genetic modification and instead reprogrammes plants in real-time, using synthetic RNA sprays that alter gene expression without leaving a clear genetic fingerprint.

Unlike GMOs, which underwent lengthy (although faulty and imperfect) regulatory reviews and must be grown from modified seeds, RNA sprays can be applied repeatedly and directly onto crops, meaning gene expression can be continuously manipulated in the field.

This creates a moving target for a safety evaluation.

Be clear: there is no fixed genome to study, no long-term data, and no labelling for consumers. By treating plants like “computers” to be constantly re-coded, this technology risks unpredictable ripple effects on plant physiology, pollinators, and human health.

Traditional GMOs were studied and showed harm, but were ignored by industry and the government.  Terrana’s RNA sprays are the next unretrievable experimental, untested at scale, and stunningly released under legal immunity, which makes this approach a vast, uncontrolled genetic experiment in our food system, our health, and our environment.

The effects of RNA sprays on our microbiome?  Unknown.

While Big Ag and Big Tech proponents tout RNA sprays as “climate‑responsive” innovations, the lack of long-term safety studies, the absence of labelling, and legal immunity represent an unchecked genetic experiment. Unlike GMOs subjected to years of oversight and litigation, this new platform bypasses those meagre safeguards entirely.

As a physician, I urge readers and policymakers alike to demand transparency, full labelling, independent safety testing, especially assessing impacts on children’s immune and reproductive health, before allowing gene-altering sprays into our food system and environment.

Approval?  No.  Moratorium.

Michelle Perro, MD, is a veteran paediatrician with over four decades of experience in acute and integrative medicine, co-founder and CEO of GMOScience. More than fifteen years ago, Dr. Perro transformed her clinical practice to include the health effects of GMOs and their associated pesticides.  She has worked as both Emergency Room Director and Attending Physician from New York’s Metropolitan Hospital/New York Medical College to UCSF Benioff Children’s Hospital, Oakland, CA.  Dr. Perro has co-authored the highly acclaimed book, ‘What’s Making Our Children Sick.